28
Sep
2020
Small Molecules Against RNA Targets: Jennifer Petter on The Long Run
Today’s guest on The Long Run is Jennifer Petter. She is the founder and chief scientific officer of Waltham, Massachusetts-based Arrakis Therapeutics. Jennifer is a medicinal chemist who has spent her career thinking about how to make small molecules with all the classic Lipinski “Rule of 5” characteristics against protein targets. Five years ago, when she was looking for a... Read More
24
Sep
2020
Illumina’s Bet on Early Cancer Detection & ESMO Highlights
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Sep
2020
Designing ‘Hyperstable Minibinders’ Against SARS-CoV-2: Q&A With David Baker
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Sep
2020
Moderna and Pfizer’s Vaccine Transparency, Gilead’s Megadeal and a Tribute to Bill Sr.
Before diving into a big week in biotech, let’s pause to think about the life of a tremendous human being we can learn from. RIP Bill Gates Sr. died at age 94. He had Alzheimer’s. The father of one of the world’s richest men was a prominent lawyer, and deeply engaged civic-minded figure in my hometown of Seattle. The older... Read More
10
Sep
2020
Industry and Academia Take a Stand for Science
Science is under attack. The FDA and the CDC have seen their credibility tarnished, largely because of the relentless pressure, and lies, of certain political leaders. The pharmaceutical industry, built on a bedrock of science, knows darn well that the whole business will come crumbling down if the world continues indulging in this bottomless cynicism and nihilism that says everything... Read More
9
Sep
2020
Recursion Pulls In $239M for AI Drug Discovery, Bayer Bets on Fibrosis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Sep
2020
Becoming a Biotech VC: Otello Stampacchia on The Long Run
Today’s guest on The Long Run is Otello Stampacchia. He’s the founder and managing director of Omega Funds. Otello started Omega in 2004, and it’s now on Fund VI. Based in Boston, Omega has $1 billion under management, and invests in a wide variety of biotech companies – early stage, later stage, American, European, oncology, immunology, rare disease. There’s a... Read More
3
Sep
2020
FDA and CDC Credibility Tarnished; Pfizer Sprints Ahead With COVID19 Vaccine
Credibility takes years to build. It can crumble in seconds. Repairs can take a lifetime. The FDA and the CDC are two of the American public health agencies that became global models of excellence after World War II. We should remember that, and perhaps the FDA and CDC should plaster it up on their walls as a reminder. Both agencies... Read More
20
Aug
2020
Spiritual Renewal in the North Cascades, and Facing Homelessness
All of us need some time and space for spiritual renewal. Especially in a year like 2020. Mountain climbing does it for me. Last weekend, I was fortunate to get out to Mt. Shuksan in the remote North Cascades of Washington. It was a gorgeous climb, led by my friends and partners at Alpine Ascents International. The climb was a... Read More
13
Aug
2020
A Microbiome Turnaround, Novavax Gears Up, & Moderna Commits to 100m Doses
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Aug
2020
From Rio to Rome: Rosana Kapeller on The Long Run
Today’s guest on The Long Run is Rosana Kapeller. She’s the president and CEO of Cambridge, Mass.-based ROME Therapeutics. ROME aims to discover and develop drugs based on emerging science in what is sometimes called the “repeatome.” These are long repeat stretches of DNA that scientists until recently knew very little about, and still have a lot to learn about... Read More
6
Aug
2020
GSK’s BCMA Antibody Gets OK, Biogen Teams With Denali & A Telemedicine Megadeal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Jul
2020
Pfizer Secures $2B for COVID-19 Vaccine, BioNTech Raises $500M, & Our Test
When Donald Trump first considered a run for president in 2000, he never rose above 1 percent in the polls. America changed in the early years of the 21st century. Trump was always good at harnessing tabloid media weaknesses to his advantage. When our information commons shifted to a 24/7 advertising-based attention-grab economy on the Internet and TV, he was... Read More
21
Jul
2020
The Road Less Traveled in Biotech: Abe Ceesay on The Long Run
Today’s guest on The Long Run is Abe Ceesay. He’s the CEO of Cambridge, Mass.-based Tiburio Therapeutics. The company is developing a couple of drug candidates for rare neuroendocrine tumors. It raised $31 million in a Series A financing in January 2019 from NEA, Lundbeckford Ventures, Longitude Capital, and Alexandria Real Estate Equities. Abe is in his early 40s, and... Read More
16
Jul
2020
Standing With Fauci, Positive Moderna Vaccine Data, and Blueprint’s Megadeal
Last week in these pages, I wrote a full-throated defense of Tony Fauci. A few days later, the White House sadly started doing what it so often does. It embarked on a dirty tricks smear campaign against someone who speaks inconvenient truth to the public. Peter Navarro, who doesn’t know what he’s talking about when it comes to public health... Read More
9
Jul
2020
Novavax Nabs $1.6B, BD Secures Fast Antigen Test OK, & a Tribute to Tony Fauci
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Jul
2020
Writing in the Language of DNA: Kevin Ness on The Long Run
Today’s guest on The Long Run is Kevin Ness. He’s the CEO of Boulder, CO-based Inscripta. This is a startup that calls itself the “digital genome engineering company.” The aspiration, which Inscripta described in a statement last December, was to create: The world’s first fully automated benchtop instrument for genome-scale engineering. Consisting of an instrument, consumables, software, and assays, it... Read More
1
Jul
2020
Pfizer, BioNTech Vaccine Shows Life, but Cases Surge, Testing Falters & Prices Haunt
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Jun
2020
The Exponential Curves Re-Emerge
The curves are telling the story. They were flat for a while. Now they’re heading up the exponential slope again. Texas, Arizona, Florida – and even California, which did so well for so long – are among the couple dozen states that are beginning to look up at those scary curves of new COVID-19 cases. We still have no idea... Read More
22
Jun
2020
Codiak Scales Up Exosome Capabilities, Snags $72.5M from Sarepta
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.